Supernus Pharmaceuticals Q1 Sales $143.600M Miss $145.832M Estimate
Portfolio Pulse from Benzinga Newsdesk
Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q1 sales of $143.600M, missing the consensus estimate of $145.832M by 1.53% and marking a 6.61% decrease from the previous year's sales of $153.764M.
May 08, 2024 | 9:21 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Supernus Pharmaceuticals reported a miss in Q1 sales against analyst estimates, with a year-over-year decrease.
Missing sales estimates and reporting a year-over-year decrease in sales are typically seen as negative indicators by the market, likely leading to a short-term negative impact on SUPN's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100